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Abstract
In vertebrates and arthropods, blood clotting involves the establishment of a plug of aggregated thrombocytes (the cellular
clot) and an extracellular fibrillar clot formed by the polymerization of the structural protein of the clot, which is fibrin in
mammals, plasma lipoprotein in crustaceans, and coagulin in the horseshoe crab, Limulus polyphemus. Both elements of the
clot function to staunch bleeding. Additionally, the extracellular clot functions as an agent of the innate immune system by
providing a passive anti-microbial barrier and microbial entrapment device, which functions directly at the site of wounds to
the integument. Here we show that, in addition to these passive functions in immunity, the plasma lipoprotein clot of
lobster, the coagulin clot of Limulus, and both the platelet thrombus and the fibrin clot of mammals (human, mouse)
operate to capture lipopolysaccharide (LPS, endotoxin). The lipid A core of LPS is the principal agent of gram-negative
septicemia, which is responsible for more than 100,000 human deaths annually in the United States and is similarly toxic to
arthropods. Quantification using the Limulus Amebocyte Lysate (LAL) test shows that clots capture significant quantities of
LPS and fluorescent-labeled LPS can be seen by microscopy to decorate the clot fibrils. Thrombi generated in the living
mouse accumulate LPS in vivo. It is suggested that capture of LPS released from gram-negative bacteria entrapped by the
blood clot operates to protect against the disease that might be caused by its systemic dispersal.
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morbidity and mortality in humans and arthropods that experience infection by Gram-negative bacteria[8,9], immunologists are
interested in the systems for its inactivation and sequestration[10,11]. We find that the extracellular fibrin clot and the
platelet thrombus of the mammalian clotting system both bind
LPS, as does the extracellular coagulin clot of the horseshoe crab,
Limulus polyphemus, and the VHDL clot of the American lobster. It
is suggested that the capture of LPS by the blood clot serves to
reduce the dissemination of LPS released by Gram-negative
bacteria that become entrapped in the clot following wounding of
the integument, thus reducing the possibility that LPS from that
source could cause systemic disease.

Introduction
Higher animals cope with invading pathogens by deploying a
variety of defense systems that involve specialized immune defense
cells and effector proteins and peptides that are found at the
integumental surface and in the blood. The cellular and humoral
components of the immune system function to neutralize and clear
invading pathogens and foreign molecules introduced by pathogens, several of which are toxins or virulence factors. The fibrillar
blood clot contributes to immunity in the arthropod, Limulus
polyphemus (the American horseshoe crab)[1] and mammals[2–4]
by immobilizing[2,3] and killing[4] invading microbes and thereby
preventing their dissemination throughout the internal milieu. The
clot of Limulus is a polymer of the protein coagulin[5] and the clot
of mammals is a polymer of fibrin[6]. The clot of the American
lobster, Homarus americanus, the third animal in our study, is a
polymer of a plasma protein, variously named clotting protein and
very high density lipoprotein (VHDL). In all three species, these
proteins polymerize into the fibrils of a robust extracellular matrix.
In addition to the passive entrapment of microbes invading at
wound sites, the present report provides evidence for an active
participation of the clot in immunity by its ability to capture and
sequester the important microbial toxin, lipopolysaccharide (LPS,
endotoxin). LPS is the principal lipid of the outer lamella of the
outer membrane of Gram-negative bacteria[7] and is continuously
shed into the environment by populations of these bacteria.
Because lipid A, the central component of LPS, is a major agent of
PLOS ONE | www.plosone.org

Materials and Methods
Materials
The following variants of LPS were used in these experiments:
Salmonella minnesota R595 (Re) from List Biological Laboratories,
Inc., cat # 304; Escherichia coli 011:B4 from Sigma-Aldrich, St
Louis, MO cat # L2630 and F3665l (FITC conjugate); Escherichia
coli 055:B5 from Sigma-Aldrich cat # L2880 and L2630 (FITC
conjugate) and from Invitrogen Corporation, Carlsbad, CA, Cat
# L-23351 (Alexa Fluor 488 conjugate); Escherichia coli O113:H10
from Associates of Cape Cod, Falmouth, MA, Cat # E0125
(Control standard endotoxin). Polymyxin B was from SigmaAldrich, Cat # P-1004 and Invitrogen Corp. cat # PI3236
(Oregon Green 514 conjugate). The Pyrotell LAL test reagent was
1
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from Associates of Cape Cod, cat # G5250. Human Research
Grade Fibrinogen and Factor XIII were from Haematologic
Technologies, Essex Junction, VT cat # HCI-0150R. Human
plasma-derived thrombin was a generous gift from Dr. John W.
Fenton (NY State Department of Health, Albany, NY). LPS-free
human plasma-derived thrombin (800–1200 IU/ml) and fibrinogen (55–85 mg/ml) (Evithrombin and Human Fibrinogen/Evicel)
were obtained from the Ethicon Division of Johnson & Johnson,
NCK 63713-390-11, lot # Q51T030.

the ocean unharmed. Hemolymph was removed from adult
lobsters by aspiration from the heart and 30 mL droplets of fresh
hemolymph were placed on the surface of plastic Petri dishes,
where they soon clotted. Clots were incubated with LPS during or
shortly after clotting or were extracted with detergent (0.5%
Triton X-100 in 0.5 M NaCl, 10 mM CaCl2, 10 mM Tris,
pH 7.3) and then incubated with LPS.

Microscopy
FITC-LPS (E. coli, 055:B5, 3.9 mg FITC/mg LPS and E. coli
011:B4, Sigma, St Louis, MO) was suspended in Tris-buffered
saline (0.5 M NaCl, 0.01 M Tris, pH 7.3 (lobster, Limulus), or
0.15 M NaCl, 0.01 M Tris, pH 7.3 (human, mouse)) then
sonicated vigorously with a tip sonicator to reduce the size of
the LPS micelles. Fibrin (human, mouse), coagulin (Limulus) and
VLDL (lobster) clots on Petri dish surfaces were rinsed with saline,
incubated with 0.4 mg/mL FITC-LPS for 1–2 h at room T, then
the preparations were washed with saline and examined with the
fluorescence microscope. The incubation and wash buffers
sometimes contained elevated salt (1.0 M NaCl) or 2 M urea
(Schwarz/Mann, Cambridge, MA, ultrapure; purged of cyanate
ion by treatment with AG 501-X8 ion exchange resin, Bio-Rad,
Richmond CA). Alternatively, clots were incubated with unlabeled
LPS, washed, then incubated with biodipy- or Oregon Green 514labeled polymyxin B (Invitrogen, Carlsbad, CA), a reagent that
binds selectively to LPS[16], and examined with the fluorescence
microscope. Control LPS-free clots treated with Oregon Green
514-polymyxin B failed to stain.

Fibrin clot (mouse, human)
Human blood was drawn into 0.1 volumes of citrated saline
(Sigma cat # C7165) and the blood cells and platelets were
removed by centrifugation at 3006g610 minutes and then the
supernatant re-spun at 5,0006g65 minutes. The citrated, plateletdepleted plasma (PDP) was stored in aliquots at 280uC. Human
plasma was obtained from the corresponding author, Peter
Armstrong, by the second author, Frederick Rickles, who is a
physician, and is qualified to draw blood. Peter Armstrong gave his
informed consent for the withdrawal of his blood for use in this
investigation. This was conducted under IRB protocol # 2001-P001867 issued by Harvard University to Professor Bruce Furie,
Beth Israel Deaconess Medical Center, Boston, MA and the
Marine Biological Laboratory, Woods Hole, MA. Mouse blood
was aspirated into 0.1 volumes of citrated saline-dextrose from the
vena cava of anesthetized mice and the blood cells were removed
by centrifugation. Clotting was initiated by adding thrombin (1–
4 U/mL-human) or Thromboplastin C Plus (Dade division,
Baxter Scientific Products, Miami, FL-mouse) or by re-calcifying
the plasma. The Beth Israel Deaconess Medical Center Institutional Animal Care and Use Committee approved all animal care
and experimental procedures. Human clots were also prepared by
allowing a drop of freshly-drawn blood to clot on a microscope
coverglass, after which the cells were lysed by treatment with 0.5%
Triton X-100 in Tris-buffered saline. The fibrin clot was also
prepared by the thrombin-mediated proteolysis of purified human
fibrinogen. A preparation of 0.5 mg/mL fibrinogen in 10 mM
Ca2+, 0.15 M NaCl, 20 mM Tris, pH 7.3, with or without 5 mg/
mL Factor XIII, was induced to clot by the addition of 1 U/mL
thrombin (37uC, 1–3 h)[12]. The e-amino groups of the arginine
and lysine residues of the fibrin clot were derivatized, respectively,
with phenylglyoxal [13] and trinitrobenzene sulfonate (TNBS)
[14].

Intravital microscopy of the murine thrombus
Intravital videomicroscopy of the cremaster muscle arterial
circulation of wild-type C57BL/6J mice was performed as
described by Falati et al. [17]. The Beth Israel Deaconess Medical
Center Institutional Animal Care and Use Committee approved
all animal care and experimental procedures. Mice were preanesthetized with ketamine, xylazine, and atropine and were
cannulated via the jugular vein. The cremaster muscle was
exteriorized onto a transparent observation platform and kept
moist with bicarbonate-buffered isotonic saline maintained at
36uC. Nembutal for maintenance of anesthesia, AlexaFluor 647labeled rat anti-mouse CD41 antibody (Fab fragment, clone
MWReg30, Emfret Analytics, Eibelstadt, Germany) for immunostaining of the platelet thrombus, and AlexaFluor 488-labeled LPS
(E. coli serotype 055:B5, molar labeling index 0.46, Invitrogen)
were introduced into the circulation via the jugular cannula. At the
completion of the experiment, the mouse was euthanized with a
lethal dose of Nembutal administered through the jugular cannula.
Each of two mice received 5 mg of LPS delivered in 100 mL of
saline. Direct observation of arteries servicing the cremaster
muscle was conducted with an Olympus AX microscope with 640
0.6 and 660 0.9 water-immersion objectives[18].
To provoke thrombus formation, the vessel wall of the artery
was subjected to injury with the beam of a Micropoint Laser
(Photonics Instrument) focused through the microscope objective.
Digital images of the resulting thrombus were captured for
transmitted visible light, and at the emission maxima for the
AlexaFluor 488 and 647 reporter dyes to document the dynamics
of thrombus formation, as previously described[17] for the capture
of AlexaFluor 488-labeled LPS in the thrombus. Control
sequences of laser-provoked thrombi were collected at these two
wave lengths prior to introduction of the AlexaFluor 488-labeled
LPS, then the labeled LPS was introduced into the system and
additional thrombi were provoked and filmed.

Coagulin clot (Limulus)
Adult horseshoe crabs obtained from the Marine Biological
Laboratory, Woods Hole, MA, were maintained in running
seawater aquaria and fed thrice weekly with lobster muscle. After
use, the animals were returned unharmed to the ocean. Horseshoe
crab plasma was prepared as described previously[15]. A blood
clot suitable for microscopic study was prepared as follows: two
drops of hemolymph were collected by cardiac puncture into a
35 mm polystyrene Petri dish containing 1 mL pyrogen-free 3%
NaCl (Travenol, Deerfield, IL, cat. # 2A1353) and incubated for
5 min at room temperature (T) to allow the blood cells to attach to
the dish surface. The saline was then replaced with sterile-filtered
Limulus plasma and incubated for 2–3 h at room T. During this
period, the blood cells flatten on the dish surface, degranulate to
release the proteins for clot formation, and establish a coagulin clot
above the flattened cells.

Plasma lipoprotein clot (American lobster)
Lobsters were maintained in individual cages in running sea
water and were fed squid. After use, the lobsters were returned to
PLOS ONE | www.plosone.org
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the presence of Limulus plasma did not affect this detection limit,
indicating that plasma did not contain inhibitors of the LAL test.
Blood clotting in the horseshoe crab is initiated by exocytosis of the
blood cells to release coagulogen, the protein that is cleaved to
develop the coagulin clot, and to initiate blood cell aggregation to
form the cellular thrombus[24]. Exocytosis releases a suite of LPSbinding proteins as well, which include anti-LPS factor (ALF), a
cationic protein that binds and detoxifies LPS[25] and Factor C, a
LPS-activated protease[26]. These soluble proteins make no
apparent contribution to removal of LPS during clotting nor do
they interfere with the LAL test - serum produced by exposure of
whole blood to the calcium ionophore A23187 (10 mM), which
provokes the same exocytosis reaction as does LPS[27] and could
be presumed to result in the same release of soluble LPS-binding
proteins from the secretory granules of the blood cells, fails to
reduce the sensitivity of the LAL test (data not shown). Thus,
essentially all of the LPS removed during clotting of whole blood of
the horseshoe crab is removed by the blood clot. The blood clot of
the lobster showed a measurable, but less effective ability to
capture LPS than did the Limulus clot (Table 2).
The clot produced in vitro by whole human blood has been
reported to capture approximately 1 mg of LPS per mL of
blood[28]. The mammalian clot has two elements - the
extracellular fibrin clot and the cellular thrombus, the latter of
which is composed principally of aggregated blood platelets[6].
Capture of LPS appears to be largely a function of the platelet
thrombus/fibrin clot because we found a similar capture efficiency
for the clots produced by platelet-rich plasma, which was depleted
of red cells and nucleated blood cells (Table 3) with the fibrin clot
being responsible for the capture of most of the LPS in this in vitro
system (Table 4).
Fluoresceinated LPS decorated the fibrils of the mammalian,
lobster, and Limulus blood clots as seen by microscopic examination (Figure 1A–D). Human clots prepared from PDP (Fig. 1A) or
from whole blood (not shown) were decorated with FITC-LPS.
Decoration of the fibrin clot by LPS was inhibited in the presence
of a ten-fold molar excess of polymyxin B, an LPS-binding
molecule (not shown). At least two possibilities exist by which LPS
binding is mediated - either LPS binds directly to the structural
protein of the clot (fibrin, VHDL, or coagulin) or LPS binds to one
or more ‘‘adaptor’’ proteins from the plasma or hemolymph that
themselves become linked to the clot, where they then bind LPS. A
variety of proteins from plasma or hemolymph are known to
decorate the fibrin and coagulin clots[29,30] and one or more of
these might be an adaptor protein responsible for LPS binding to
the structural elements of the clot. Instead, binding to the
mammalian clot appears to result from a direct association of
LPS with fibrin. Depletion of plasma of LPS-binding proteins by
exposure to LPS-Sepharose prior to the initiation of clotting failed
to affect the subsequent binding of LPS to the clot. Furthermore,
FITC-LPS decorates clots prepared from purified fibrinogen (free
of contaminating proteins) that was induced to polymerize by
thrombin-catalyzed proteolytic cleavage (Fig. 1F).
The difficulties of quantifying the fluorescence images due to the
indeterminate thickness of the fibrin fibrils and the difficulty of
working at high concentrations of LPS have frustrated the
investigation of competitive inhibition of FITC-LPS binding by
unlabeled LPS. Binding to the mammalian fibrin and Limulus
coagulin clots was not noticeably affected by high salt (1.0 M
NaCl) or 2 M urea (not shown), suggesting that binding is
relatively strong. Binding of LPS to both clots appears to be
selective because AlexaFluor 488-conjugated liposomes composed
of a 6:1 ratio of phosphaticylcholine:phosphatidylethanolamine, as

Image analysis
Image analysis used Slidebook (Intelligent Imaging Innovations). Images were captured digitally at up to 50 frames/sec. The
analysis program assigned an intensity value between 0 and 4095
for each pixel of each frame. For display that value is converted to
pseudo-color of associated intensity for the 488 (green) and 647
(red) channels. Background values were established in a rectangle
positioned upstream of the thrombus and prior to its formation.
This value was subtracted from each pixel to yield the thrombusspecific fluorescent intensities for each pixel. The analysis delivered
colored frames that combined sequential transmitted bright-field,
and fluorescent images in the green and red channels and a
graphical summary of the variation with time of the specific
fluorescence intensity for the entire image in green and red
channels.

LAL assay for LPS
The Pyrotell LAL (Limulus amebocyte lysate) kit (Associates of
Cape Cod, Falmouth, MA, cat # G5250) was used to confirm the
absence of exogenous endotoxin (LPS) in the reagents and to
quantify the capture of LPS by the blood clot of the horseshoe
crab, lobster, and human using the manufacturer’s instructions.
LPS (E. coli 0113:H10, ‘‘Control Standard Endotoxin’’, cat E0125,
Associates of Cape Cod) dissolved at the recommended concentration of 25 mg/mL in pyrogen-free distilled water with extensive
sonication was added to freshly drawn blood and the blood was
incubated for a time sufficient to allow for clotting and clot
contraction to occur. Samples of the resulting serum were diluted
1:10–1:1000 in pyrogen-free water and the concentration of LPS
that remained in the serum was quantified by coagulation of the
LAL reagent. Prior to being subject to the LAL assay, human
serum was diluted 1:10 and incubated at 70uC for 10 min to
inactivate endogenous inhibitors of the LAL test[19,20], principally a2-macroglobulin[21]. In our hands, this assay was able to
detect 0.1 ng/mL of LPS diluted in saline. The LPS capture
efficiency of the clot was estimated by determining the maximum
quantity of LPS that could be removed from whole blood during
the formation of the blood clot. Controls included the determination of LPS concentrations in plasma and serum prepared at the
same time from the same animal.

AlexaFluor 488-labeled liposomes
A 6:1 mixture of phosphatidylcholine: phosphatidylethanolamine (Avanti Polar Lipids, Alabaster AL) was dissolved in
anhydrous chloroform and the chloroform evaporated with a
stream of nitrogen. The dried lipid mixture was suspended in
0.1 M NaHCO3 containing 0.1 mg/mL AlexaFluor 488 5-TFP
(Invitrogen) and sonicated until clear. After incubation overnight
at 4uC, the preparation was separated from unconjugated dye by
dialysis.

Results
Capture of LPS by the blood clot was quantified using the
Pyrotell version of the LAL (Limulus Amebocyte Lysate) test,
which utilizes LPS-elicited coagulation of the LAL reagent to
quantify the concentration of LPS in a given sample. The assay
was routinely able to detect 0.1 ng/mL of LPS added to pyrogenfree water. The Limulus blood clot was able to reduce the
concentration of LPS free in solution to below 10 ng/mL for initial
concentrations of LPS as high as 3 mg/mL (Table 1). Although
horseshoe crab plasma contains a form of C-reactive protein that
binds LPS[22] and large quantities of protease inhibitors that
might interfere with the proteases involved with the LAL test[23],
PLOS ONE | www.plosone.org
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Table 1. Capture of LPS by the Limulus blood clot1.

Initial LPS in the blood
(ng/mL)

Dilution prior to assay

LAL coagulation

Maximum concentration of Minimum LPS capture per
LPS in the serum (ng/mL)
1 mL blood (ng)

100

10

No

1

99

400

10

No

1

399

1000

10

Yes

1000

100

No

10

990

3000

100

No

10

2990

1
LPS from E. coli serotype O113:H10 was added to freshly drawn Limulus hemolymph and the preparation was incubated to allow the blood to clot and the clot to
retract. The serum was diluted with pyrogen-free deionized water and assayed for residual LPS using the Pyrotell assay, in which a positive result is shown by
coagulation of the LAL test reagent (column 3). The assay was sensitive to 0.1 ng/mL LPS both in water and in Limulus plasma (data not shown). Dilution of the samples
elevated the minimum detectible concentration of LPS to the values shown in column 4 of the table. The amount of LPS removed from solution by the clot formed from
1 mL of whole blood is shown in column 5. Selected data points from this individual trial were replicated in 3 additional trials.
doi:10.1371/journal.pone.0080192.t001

a control for non-specific lipid interaction with the clots, failed to
decorate either type of clot (not shown).
LPS consists of three covalently-linked elements, the lipid A
moiety with six or seven hydrocarbon chains attached to a
phosphorylated glucosamine disaccharide head group, a core
oligosaccharide bound to the lipid A moiety via keto-deoxyoctanate
(KDO) residues, and the O-antigen polysaccharide chain, which
can be hundreds of monosaccharide residues long in some variants
of LPS[7]. Binding of LPS to the fibrin clot does not appear to
require the core oligosaccharide or the O-antigen carbohydrate
chain because a form of LPS that lacks these constituents, LPS from
Streptococcus minnesota R595 (Re), bound to the fibrin clot (Fig. 1E).
Because basic amino acids feature importantly in the wellcharacterized binding motifs of LPS-binding proteins [31,32], it is
of interest to determine if arginine and lysine play a role in the
capture of LPS by the blood clot. Indeed derivitization of the eamino group of the lysine residues of the fibrin clot with TNBS
(Figure 2a) and arginine residues of the fibrin (Figure 2b) and
coagulin (figure 2c) clots with phenylglyoxal did reduce capture.
To determine if LPS capture by the clot can occur in vivo, we
analyzed video records produced by intravital microscopy of the

thrombus developed by laser-elicited damage to the vascular
endothelium of arteries perfusing the cremaster muscle of the
living mouse. The mice were infused with AlexaFluor 488-labeled
LPS introduced into the blood. In this system, the platelet
thrombus that forms at the locus of a laser-induced injury of the
blood vessel wall was identified by the adherence of platelets
labeled with an AlexaFluor 647-labeled antibody against CD41, a
cell surface protein of the blood platelet. The green label of LPS
was found to be co-localized with the red label of the platelet
thrombus (yellow pixels, Fig. 3A) and was seen at the thrombusvessel wall interface and extending beyond the bounds of the
thrombus (arrow, Fig. 3A). This is a location of the fibrin clot
external to the bounds of the platelet thrombus[33] and the green
signal is consistent with the possibility that, in addition to the
platelet thrombus, the labeled LPS has bound to the fibrin clot that
forms at the juncture of thrombus and blood vessel wall. A fibrin
clot also is present within the platelet thrombus[17] and it is not
possible to determine if the majority of the yellow signal, where the
green and red fluorophores co-localize, is due to direct binding of
the fluoresceinated LPS to platelets or to fibrin contained within
the platelet thrombus. These clots are dynamic, with episodes of

Table 2. Capture of LPS by the lobster blood clot1.

Initial LPS in the blood
(ng/mL)

Dilution prior to assay

LAL coagulation

Maximum concentration of
LPS in the serum (ng/mL)

Minimum LPS capture per
1 mL blood (ng)

100

100

Yes

100

100

Yes

100

150

100

200

No

15

85

No

20

80

100
100

200

No

20

80

400

No

40

60

100

500

No

50

50

800

1000

Yes

800

1333

Yes

800

2000

No

200

600

1
LPS was added to freshly collected lobster blood at the concentrations indicated in column 1, then the blood was allowed to clot. After a 1 h incubation at 23uC, the
serum was collected and diluted in LPS-free water as indicated in column 2 and assayed by the LAL test (column 3), as described in Materials and Methods. The
sensitivity of the assay when LPS was added directly to cell-free lobster hemolymph was 0.1 ng/mL LPS, but due to the dilution of the experimental samples, the
detection limit of the maximum concentration of free LPS remaining in solution in the serum was correspondingly elevated, as indicated in column 4. Subtraction of
maximum free concentration of LPS from the initial concentration yields the minimum amount of LPS captured by the clot produced by 1 mL of lobster blood (column
5). Selected data points from this individual trial were replicated in 1 additional trial.
doi:10.1371/journal.pone.0080192.t002
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Table 3. Capture of LPS by the complete human blood clot (platelet thrombus and fibrin clot)1.

LAL coagulation

Maximum concentration of LPS in
the serum (ng/mL)

Minimum LPS capture per
thrombus of 1 mL of plateletrich plasma (ng)

10

No

1

9

10

Yes

100

50

No

5

95

200

50

No

5

195

200

100

No

10

190

400

100

No

10

390

1000

250

Yes

1000

500

No

50

950

Dilution prior to
Initial LPS in the blood (ng/mL) assay
10
100

1

LPS was added to a suspension of platelet-rich plasma at the concentrations indicated in column 1, after which the suspension was induced to clot by the addition of
LPS-free recombinant thrombin. After a 1 h incubation at 37uC, the clot was removed and the serum was diluted in LPS-free water as indicated in column 2, heated for
10 min at 70uC to inactivate endogenous inhibitors of the LAL test (presumably a2-macroglobulin), and assayed by the LAL test (column 3), as described in Materials and
Methods. The sensitivity of the assay was 0.1 ng/mL LPS, but due to the dilution of the experimental samples, the maximum concentration of free LPS remaining in
solution in the serum was correspondingly elevated, as indicated in column 4. Subtraction of the maximum free concentration of LPS from the initial concentration
yields the minimum amount of LPS captured by 1 mL of platelet-rich plasma (column 5). This is our sole trial for this condition and serves as a replicate for data reported
previously by Levin et al [28].
doi:10.1371/journal.pone.0080192.t003

fabric of the clot[3,9] and by adhesive capture at the surface of the
clot[1]. The mammalian clot can kill some pathogenic bacteria[4].
These processes function to immobilize and destroy microbes at
the wound site, impeding their ability to cause systemic disease.
Indirect evidence for a role of the clot in immunity is suggested by
the presence of fibrinolytic protease systems as essential virulence
factors for a broad variety of microbial, protozoan, and metazoan
parasites[34,35], suggesting that destruction of the clot is essential,
in these instances, for pathogen virulence. Microbes can activate
the exocytosis of the proteins of the clotting pathway from
secretory granules of the blood cells[27,36] and coagulation of the
coagulin clot[5] in Limulus and can activate the clotting pathway of

expansion as platelets accumulate at the injury site and abrupt
events of retraction, when portions of the thrombus break free and
are carried away with the flowing blood (video S1). The intensity
of the 488 nm signal, a measure of the amount of LPS associated
with the clot, shows close temporal correlation with the 647 nm
signal, a measure of the volume of the thrombus (Fig 3B).

Discussion
An important role for the blood clot in immune defense is
suggested by a variety of observations. The mammalian and
Limulus clots capture microbes both by entrapment within the

Table 4. Capture of LPS by the human fibrin clot1.

LAL coagulation

Maximum concentration of LPS in
the serum (ng/mL)

Minimum LPS capture per fibrin
clot of 1 mL of platelet-depleted
plasma

10

No

1

9

10

Yes

100

10

Yes

100

50

No

5

95

200

50

No

5

195

200

100

No

10

190

400

100

No

10

390

400

100

No

10

390

400

100

Yes

1000

250

No

25

975

1000

500

No

50

950

Dilution prior to
Initial LPS in the blood (ng/mL) assay
10
100

1

LPS was added to a suspension of platelet-depleted plasma at the concentrations indicated in column 1, then the suspension was induced to clot by the addition of
LPS-free recombinant thrombin. This is plasma from the same sample of blood used for Table 3, after removal of the platelets by centrifugation with a microcentrifuge
at top speed. After a 1 h incubation at 37uC, the fibrin clot was removed and the serum was diluted in LPS-free water as indicated in column 2, heated for 10 min at
70uC, and assayed by the LAL test (column 3), as described in Materials and Methods. The sensitivity of the assay was 0.1 ng/mL LPS, but due to the dilution of the
experimental samples, the maximum concentration of free LPS remaining in solution in the serum was correspondingly elevated, as indicated in column 4. Subtraction
of maximum free concentration of LPS from the initial concentration yields the minimum amount of LPS captured by 1 mL of platelet-rich plasma (column 5). Selected
data points from this individual trial were replicated in 7 additional trials.
doi:10.1371/journal.pone.0080192.t004
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from a disseminated activation of clotting and an arrest of the
circulation of the hemolymph[9,43,44]. Probably because LPS is
such a potent toxin, long-lived animals, as exemplified by humans,
lobster, and Limulus, have multiple systems for recognition and
detoxification of LPS. Activation of the canonical LPS signaling
pathway in mammals involves the binding of LPS to lipopolysaccharide-binding protein (LBP) and CD14 and the binding of that
complex to an MD-2-toll-like receptor 4 (TLR4) complex at the
surfaces of phagocytes[45–47]. Capture by the murine platelet
thrombus may involve binding of LPS to platelet TLR4 and CD62
at the surfaces of platelets[46,47]. Several other discrete pathways
for clearance and detoxification of LPS have been identified in
mammals[10,11]. In the horseshoe crab, factor C mediates the
best-characterized LPS recognition system. Factor C is an LPSactivated serine protease, which operates as a pleiotropic LPSbinding agent. Factor C activation is the initial step in the clotting
cascade in Limulus[26], mediates the binding of LPS to the surfaces
of horseshoe crab hemocytes[48], and promotes hemocyte
exocytosis. The latter event leads to the release of coagulogen
and the proteases of the clotting cascade from the hemocytes[49].
The best characterized LPS-detoxifying agent in the horseshoe
crab is ALF, a cationic protein from the hemocytes that binds and
detoxifies LPS[25]; ALF is a candidate for therapeutic use in the
management of gram-negative sepsis in humans[50].
The capture of LPS by the mammalian platelet/fibrin
thrombus, by fibrin, VLDL, and coagulin clots of mammals,
lobsters, and horseshoe crabs, respectively, represents a novel LPS
sequestration pathway. Figure 1 shows that capture involves the
direct binding of LPS to the surfaces of the clot fibrils rather than
the physical sequestration of soluble LPS into fluid compartments
of the clot. It is possible that LPS capture by the clot reduces the
concentration of LPS free in solution both in situations where the
clot is active at wounds to the integument and also for
intravascular clots. Both in humans[51] and in the horseshoe
crab[52], disseminated intravascular coagulation (DIC) is an
important feature of the pathology of Gram-negative sepsis and
is thought to contribute to the generalized organ failure that
characterizes the terminal stages of the disease in humans by
inducing small vessel thrombosis. Our demonstration of capture of
LPS by the intravascular clot in the mouse suggests that the
intravascular blood clot may reduce the concentration of
circulating LPS during this process, but one assumes that only in
the milder forms of Gram-negative sepsis would this be expected
to ameliorate the severity of pathophysiology of DIC. A variety of
therapeutic approaches to sepsis by manipulation of mammalian
blood clotting pathways (e.g. treatment of DIC) have not yet
proved dramatically successful at reducing mortality)[53]. It is
possible that improving the efficacy of binding of LPS to early
thrombus formation prior to the onset of DIC might be a rational
approach.
The binding to the mammalian fibrin clot, rather than requiring
an adaptor protein associated with the clot, appears to operate by
direct binding to fibrin. The binding does not appear to require
lectin-type interaction with carbohydrates of the O-polysaccharide
of LPS, since forms of LPS lacking this moiety bind perfectly well
to fibrin clots. The binding of LPS to fibrin and coagulin clots does
not appear to be due to ‘‘non-specific’’ lipid interaction, since
neither type of clot binds liposomes composed of the conventional
membrane-type phospholipids, phosphatidylcholine:phosphatidylethanolamine. However, LPS is acknowledged to be a ‘‘sticky’’
molecule that attaches to solid surfaces, presumably by ionic and/
or hydrophobic bonds. The best-characterized LPS binding motif
of LPS-binding proteins includes a quartet of closely apposed
lysine and arginine residues whose e-amino groups interact with

Figure 1. Decoration of the extracellular blood clot by
lipopolysaccharide (LPS). FITC-LPS (E. coli O55:B5) decorates the
fibrin fibrils of the human clot prepared from platelet-depleted plasma
(Fig 1A), the plasma lipoprotein clot of the lobster (Fig 1B), and the
coagulin fibrils of the Limulus clot (Fig. 1C). The Limulus clot shown in
Fig 1C was also immunostained with a rabbit anti-coagulin antibody
and DyLight 549 Goat anti-rabbit whole IgG second antibody to show
the location of the coagulin fibrils of the blood clot. Figure 1D shows
the same field of the Limulus blood clot as is shown in Figure 1C but
illuminated with the rhodamine filter set to show the DyLight 549
signal, demonstrating the co-localization of LPS and the coagulin
structural protein of the clot. The lipid A core of LPS is sufficient for
binding to the fibrin clot because a form of LPS that lacks carbohydrate,
LPS of S. minnesota R595 (Re), also binds to the fibrin clot (Fig. 1E). Here,
biodipy-conjugated polymyxin B, a LPS-binding probe, was used as the
fluorescent reporter for the localization of LPS. Fibrin clots prepared by
thrombin-mediated clotting of pure human fibrinogen (Hematologic
Technologies) also decorate with FITC-LPS (E. coli O55:B5) (Fig. 1F). The
micrographs were produced with a Zeiss Axioimager microscope with a
40/0.75 objective. These representative micrographs are drawn from as
many as 10 replicates (Fig. 1A) to as few as 2 replicates (Fig. 1B). Scale
bar, 50 mm.
doi:10.1371/journal.pone.0080192.g001

fibrinogen in mammals[37], the latter generally thought to be
mediated principally by interaction of LPS with the ‘‘contact
factors’’ of clotting (factors XII, XI, high-molecular-weight
kininogen and kallikrein)[38]. Additionally, activation of mammalian[39,40] and Limulus[41,42] clotting systems can trigger in
parallel a variety of other arms of the innate immune system.
The lipid A component of LPS is the causative agent of many of
the pathological reactions observed in patients with gram-negative
sepsis, a potentially lethal condition that claims more than 100,000
lives annually in the USA[8]. Horseshoe crabs are also susceptible
to the introduction of LPS into the hemocoel, with death resulting
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Figure 2. Derivitization of the e-amino groups of lysine and arginine reduces capture of LPS by the blood clot. Treatment of the fibrin
clot with TNBS to derivitize the e-amino groups of lysine reduces capture of FITC-LPS (Fig. A1, untreated control fibrin clot, fluorescent LPS; Fig. A2,
TNBS-treated fibrin clot, fluorescent LPS; Fig A3, same field as Fig A2, phase contrast). Similarly, treatment of the fibrin clot with PGO to derivitize the
e-amino groups of arginine (Fig. B1, untreated control fibrin clot, fluorescent LPS; Fig B2, PGO-treated fibrin clot, fluorescent LPS; Fig. B3, same field as
Fig B2, phase contrast) also reduces LPS capture by the clot fibrils. Treatment of the coagulin clot of Limulus with PGO reduces capture of LPS by the
clot (Fig. C1, untreated control coagulin clot; Fig. C2, PGO-treated coagulin clot). The PGO-treated specimen shows faint fluorescence of the nuclei of
the underlying blood cells but no fluorescence of the overlying coagulin clot. TNBS treatment causes cytolysis of the Limulus blood cells and
separation of the coagulin clot from the petri dish surface, preventing assessment of its effects on LPS capture in this system.
doi:10.1371/journal.pone.0080192.g002

the negatively-charged phosphates of the phospho-glucosamine
residues of the lipid A backbone [31,54,55]. Derivatization of the
e-amino groups of arginine by treatment of the fibrin (Fig. 2a) and
coagulin (Fig. 2b) clots with phenylglyoxal and derivatization of
the e-amino acids of lysine of the fibrin clot by treatment with

TNBS (Fig. 2c) reduced capture of fluoresceinated LPS, consistent
with the notion that both arginine and lysine residues of the clot
are important for LPS capture.
The binding of LPS to the fibrin, coagulin, and VLDL clots is
relatively strong, resisting treatment with high salt. The maximum

Figure 3. Capture of LPS in vivo (E. coli O55:B5) by the platelet thrombus. Intravital clots produced in large arteries of the living mouse
cremaster muscle were challenged with AlexaFluor 488-labeled LPS introduced into the circulatory system. Figure 3A: the platelet thrombus is
marked with AlexaFluor 647-labeled anti-CD41 Fab monoclonal antibody (red signal) and the location of LPS binding by AlexaFluor 488-labeled LPS
(green signal). Where the location of the platelet thrombus coincides with LPS, the signal is yellow. In addition to binding to the thrombus, LPS is
found at the interface of thrombus and blood vessel wall (arrow, green signal), which is the predominant location of the fibrin clot outside of the
bounds of the platelet thrombus. The direction of blood flow in the artery is from the top of the figure to the bottom. v, lumen of the blood vessel.
Figure 3B: time course of association of AlexaFluor 488-labeled LPS (E. coli O55:B5) with the site of the laser-provoked thrombus in vivo. Following
laser damage to the blood vessel wall of the artery of the cremaster muscle of the mouse, the thrombus enlarges gradually as platelets accumulate at
the damage site. The thrombus then shrinks precipitously as fragments of the thrombus break free and are carried away by the flowing blood. This is
reflected in the 647 signal of the AlexaFluor-647-labeled anti-CD41 antibody (red trace). The association of LPS with the thrombus, measured by the
488 signal (green trace), shows a close correlation with the volume of the thrombus. These experiments were replicated in 17 thrombi from 2 mice.
doi:10.1371/journal.pone.0080192.g003
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LPS capture capacity of the clots generated by 1 mL of blood is
approximately 3 mg for the horseshoe crab (Table 1) and 1 mg for
human (Table 3). Since each bacterial cell has approximately
3.56106 molecules of LPS or an amount of approximately
60 fg[56], 1 mg of LPS would represent the entire LPS content of
1.676107 bacterial cells.
Although the capacity of fibrin and VHDL clots to capture LPS
is relatively high, the avidity is surprisingly low, as demonstrated
by the significant quantities of LPS remaining in serum after
clotting (Tables I–IV). Any attempt to assign molar binding
parameters to this situation are complicated by the variability of
the molecular mass of monomeric LPS due to the variability of the
size of the O-polysaccharide chain even in preparations of LPS of
a given serotype. A more significant contribution to variability
derives from the tendency of LPS, an amphipathic molecule, to
exist in solution in higher order aggregates of variable size[57].
Further complicating a quantitative interpretation of the relative
contribution of this system to innate immunity is the association of
LPS with various LPS-binding proteins of the plasma[11], which
may affect association with the clot and/or affect the multimeric
aggregation state of LPS. Indeed, if a majority of the LPS in the
system is multimeric, then the molar concentration of the LPS
micelles would be far lower than that estimated by dividing the
nominal concentration of LPS by the molecular weight of the LPS
monomer, with a corresponding effect on any estimate of molar
binding parameters.
In summary, we identify here a newly recognized system for the
sequestration of the important microbial toxin, lipopolysaccharide.
Binding to the clot is suggested to be important for the capture and
sequestration of LPS released by microbes entrapped in the clot
during their entry, for example, through wounds in the

integuments. As such, sequestration of LPS provides a mechanism
for reducing the impact that would follow from the release of that
LPS into the systemic circulation.

Supporting Information
Video S1 Time-lapse video of the capture of AlexaFluor
488-labeled LPS by the intravital clot. AlexaFluor 488labeled LPS (pseudocolored green) introduced into the circulation
of a living mouse is captured by the thrombus induced by laser
ablation of the endothelial surface of the arterial wall of an artery
of the cremaster muscle of the living mouse. The laser wound was
administered at 5.5 sec into the record. The platelet thrombus is
identified by AlexaFluor 647-labeled anti-CD41 antibody (pseudocolored red). The region of overlap of the green (LPS) and red
(CD41) signals is yellow.
(AVI)

Acknowledgments
We thank Dr. Jack Levin for a critical reading of the manuscript and
Professor Bruce Furie for graciously hosting PBA as a sabbatical visitor to
his laboratory at the Beth-Israel Deaconess Medical Center and PBA and
FRR as guests in his laboratory at the Marine Biological Laboratory.

Author Contributions
Conceived and designed the experiments: PBA. Performed the experiments: MTA FRR PBA. Analyzed the data: MTA FRR PBA. Contributed
reagents/materials/analysis tools: PBA. Wrote the paper: PBA. Critiqued
the manuscript: MTA FRR.

References
1. Bosniak PA, Armstrong PB (2004) Blood clotting in Limulus immunity:
physiological impairment of clot-entrapped bacteria. BiolBull(Woods Hole)
207: 172.
2. Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, et al. (2010)
Reciprocal coupling of coagulation and innate immunity via neutrophil serine
proteases. NatMed 16: 887–896.
3. Rotstein OD (1992) Role of fibrin deposition in the pathogenesis of
intraabdominal infection. EurJClinMicrobiolInfectDis 11: 1064–1068.
4. Loof TG, Morgelin M, Johansson L, Oehmcke S, Olin AI, et al. (2011)
Coagulation, an ancestral serine protease cascade, exerts a novel function in
early immune defense. Blood 118: 2589–2598.
5. Iwanaga S, Kawabata S (1998) Evolution and phylogeny of defense molecules
associated with innate immunity in horseshoe crab. Front Biosci 3: D973–D984.
6. Furie B, Furie B C (2000) Molecular basis of blood coagulation. In: Hoffman R,
Benz EJ, Shattil SJ, Furie B, Cohen HJ, et al., editors. Hematology - Basic
Principles and Practice. 3rd ed. New York: Churchill Livingstone. pp. 1783–
1804.
7. Raetz CR, Whitfield C (2002) Lipopolysaccharide endotoxins. AnnuRevBiochem 71: 635–700.
8. Sands KE, Bates DW, Lanken PN, Graman PS, Hibberd PL, et al. (1997)
Epidemiology of sepsis syndrome in 8 academic medical centers. Academic
Medical Center Consortium Sepsis Project Working Group. JAMA 278: 234–
240.
9. Bang FB (1979) Ontogeny and phylogeny of response to gram-negative
endotoxins among the marine invertebrates. In: Cohen E, Bang FB, Levin J,
Marchalonis JJ, Pistole TG, et al., editors. Biomedical Applications of the
Horseshoe Crab (Limulidae). New York, N.Y.: Alan R. Liss. pp. 109–123.
10. Munford RS (2005) Detoxifying endotoxin: time, place and person. JEndotoxinRes 11: 69–84.
11. Gutsmann T, Muller M, Schromm AB (2009) Interactions between lipid A and
serum proteins. Adv Exp Med Biol 667: 39–51.
12. Cho J, Degen JL, Coller BS, Mosher DF (2005) Fibrin but not adsorbed
fibrinogen supports fibronectin assembly by spread platelets. Effects of the
interaction of alphaIIb beta3 with the C terminus of the fibrinogen gammachain. JBiolChem 280: 35490–35498.
13. Takahashi K (1968) The reaction of phenylglyoxal with arginine residues in
proteins. J Biol Chem 243: 6171–6179.
14. Renosto F, Seubert PA, Knudson P, Segel IH (1985) Adenosine 59phosphosulfate kinase from Penicillium chrysogenum. Determining ligand

PLOS ONE | www.plosone.org

15.

16.

17.

18.

19.

20.

21.

22.

23.
24.
25.

26.

27.
28.

8

dissociation constants of binary and ternary complexes from the kinetics of
enzyme inactivation. J Biol Chem 260: 11903–11913.
Armstrong P, Conrad M (2008) Blood collection from the American horseshoe
crab, Limulus polyphemus. JVisExp 20: http://www.jove.com/index/details.
stp?ID = 958.
Armstrong MT, Theg SM, Braun N, Wainwright N, Pardy RL, et al. (2006)
Histochemical evidence for lipid A (endotoxin) in eukaryote chloroplasts.
FASEB J 20: 2145–2146.
Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B (2002) Real-time in vivo
imaging of platelets, tissue factor and fibrin during arterial thrombus formation
in the mouse. NatMed 8: 1175–1181.
Dubois C, Atkinson B, Furie BC, Furie B (2006) Real time in vivo imaging of
platelets during thrombus formation. In: Michelson AD, editor. Platelets.
Amsterdam, The Netherlands: Academic Press/Elsevier. pp. 611–626.
Goto T, Eden S, Nordenstam G, Sundh V, Svanborg-Eden C, et al. (1994)
Endotoxin levels in sera of elderly individuals. ClinDiagnLab Immunol 1: 684–
688.
Pearson FC, Dubczak J, Weary M, Bruszer G, Donohue G (1985) Detection of
endotoxin in the plasma of patients with gram- negative bacterial sepsis by the
Limulus amoebocyte lysate assay. JClinMicrobiol 21: 865–868.
Armstrong PB, Levin J, Quigley JP (1984) Role of endogenous proteinase
inhibitors in the regulation of the blood clotting system of the horseshoe crab,
Limulus polyphemus. ThrombHaemost 52: 117–120.
Ng PM, Jin Z, Tan SS, Ho B, Ding JL (2004) C-reactive protein. A predominant
LPS-binding acute phase protein responsive to Pseudomonas infection. JEndotoxin
Res 10: 163–174.
Armstrong PB (2010) Role of a2-macroglobulin in the immune response of
invertebrates. InvertSurvival J 7: 165–180.
Levin J (1979) The Limulus test: a status report. ProgClinBiolRes 29: 235–244.
Andra J, Howe J, Garidel P, Rossle M, Richter W, et al. (2007) Mechanism of
interaction of optimized Limulus-derived cyclic peptides with endotoxins:
thermodynamic, biophysical and microbiological analysis. BiochemJ 406: 297–
307.
Nakamura T, Morita T, Iwanaga S (1986) Lipopolysaccharide-sensitive serineprotease zymogen (factor C) found in Limulus hemocytes. Isolation and
characterization. EurJBiochem 154: 511–521.
Armstrong PB, Rickles FR (1982) Endotoxin-induced degranulation of the
Limulus amebocyte. ExpCell Res 140: 15–24.
Levin J, Tomasulo PA, Oser RS (1970) Detection of endotoxin in human blood
and demonstration of an inhibitor. JLabClinMed 75: 903–911.

November 2013 | Volume 8 | Issue 11 | e80192

Capture of Lipopolysaccharide by the Blood Clot

29. Weisel JW (2005) Fibrinogen and fibrin. AdvProtein Chem 70: 247–299.
30. Armstrong PB, Armstrong MT (2003) The decorated clot: Binding of agents of
the innate immune system to the fibrils of the limulus blood clot. BiolBull 205:
201–203.
31. Ferguson AD, Welte W, Hofmann E, Lindner B, Holst O, et al. (2000) A
conserved structural motif for lipopolysaccharide recognition by procaryotic and
eucaryotic proteins. Structure 8: 585–592.
32. Park NG, Lee S, Oishi O, Aoyagi H, Iwanaga S, et al. (1992) Conformation of
tachyplesin I from Tachypleus tridentatus when interacting with lipid matrices.
Biochemistry 31: 12241–12247.
33. Furie B, Furie BC (2007) In vivo thrombus formation. JThrombHaemost 5
Suppl 1: 12–17.
34. Degen JL, Bugge TH, Goguen JD (2007) Fibrin and fibrinolysis in infection and
host defense. JThrombHaemost 5 Suppl 1: 24–31.
35. Armstrong PB (2006) Proteases and protease inhibitors: a balance of activities in
host-pathogen interaction. Immunobiology 211: 263–281.
36. Tablin F, Levin J (1988) The fine structure of the amebocyte in the blood of
Limulus polyphemus. II. The amebocyte cytoskeleton: a morphological analysis of
native, activated, and endotoxin-stimulated amebocytes. BiolBull(Woods Hole)
175: 417–429.
37. Persson K, Russell W, Morgelin M, Herwald H (2003) The conversion of
fibrinogen to fibrin at the surface of curliated Escherichia coli bacteria leads to
the generation of proinflammatory fibrinopeptides. JBiolChem 278: 31884–
31890.
38. Morrison DC, Ulevitch RJ (1978) The effects of bacterial endotoxins on host
mediation systems. A review. Am J Pathol 93: 526–618.
39. Senior RM, Skogen WF, Griffin GL, Wilner GD (1986) Effects of fibrinogen
derivatives upon the inflammatory response. Studies with human fibrinopeptide
B. JClinInvest 77: 1014–1019.
40. Frick IM, Akesson P, Herwald H, Morgelin M, Malmsten M, et al. (2006) The
contact system—a novel branch of innate immunity generating antibacterial
peptides. EMBO J 25: 5569–5578.
41. Nagai T, Kawabata S (2000) A link between blood coagulation and prophenol
oxidase activation in arthropod host defense. JBiolChem 275: 29264–29267.
42. Ariki S, Takahara S, Shibata T, Fukuoka T, Ozaki A, et al. (2008) Factor C acts
as a lipopolysaccharide-responsive C3 convertase in horseshoe crab complement
activation. JImmunol 181: 7994–8001.
43. Levin J, Bang FB (1964) The role of endotoxin in the extracellular coagulation of
Limulus blood. BullJohns Hopkins Hosp 115: 265–274.

PLOS ONE | www.plosone.org

44. Levin J (1988) The horseshoe crab: a model for gram-negative sepsis in marine
organisms and humans. ProgClinBiolRes 272: 3–15.
45. Miller SI, Ernst RK, Bader MW (2005) LPS, TLR4 and infectious disease
diversity. NatRevMicrobiol 3: 36–46.
46. Andonegui G, Kerfoot SM, McNagny K, Ebbert KV, Patel KD, et al. (2005)
Platelets express functional Toll-like receptor-4. Blood 106: 2417–2423.
47. Stahl AL, Svensson M, Morgelin M, Svanborg C, Tarr PI, et al. (2006)
Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets
through TLR4 and CD62 and is detected on circulating platelets in patients with
hemolytic uremic syndrome. Blood 108: 167–176.
48. Koshiba T, Hashii T, Kawabata S (2007) A structural perspective on the
interaction between lipopolysaccharide and factor C, a receptor involved in
recognition of Gram-negative bacteria. JBiolChem 282: 3962–3967.
49. Ariki S, Koori K, Osaki T, Motoyama K, Inamori K, et al. (2004) A serine
protease zymogen functions as a pattern-recognition receptor for lipopolysaccharides. ProcNatlAcadSciUSA 101: 953–958.
50. Roth RI, Su D, Child AH, Wainwright NR, Levin J (1998) Limulus
antilipopolysaccharide factor prevents mortality late in the course of endotoxemia. JInfectDis 177: 388–394.
51. Opal SM (2007) The host response to endotoxin, antilipopolysaccharide
strategies, and the management of severe sepsis. Int J Med Microbiol 297:
365–377.
52. Bang FB (1956) A bacterial disease of Limulus polyphemus. BullJohns Hopkins
Hosp 98: 325–351.
53. Wynn J, Cornell TT, Wong HR, Shanley TP, Wheeler DS (2010) The host
response to sepsis and developmental impact. Pediatrics 125: 1031–1041.
54. Jerala R (2007) Structural biology of the LPS recognition. Int J Med Microbiol
297: 353–363.
55. Park BS, Song DH, Kim HM, Choi BS, Lee H, et al. (2009) The structural basis
of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458:
1191–1195.
56. Nikaido H, Vaara M (1987) Outer membrane. In: Niedhardt FC, Ingraham JL,
Low KB, Magasanik B, Schaechter M, et al., editors. Escherichia coli and
Salmonella typhimurium Cellular and Molecular Biology. Washington, D.C.:
American Society for Microbiology. pp. 7–22.
57. Richter W, Vogel V, Howe J, Steiniger F, Brauser A, et al. (2011) Morphology,
size distribution, and aggregate structure of lipopolysaccharide and lipid A
dispersions from enterobacterial origin. InnateImmun 17: 427–438.

9

November 2013 | Volume 8 | Issue 11 | e80192

